Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743866 | 0.85 | MAPK1 (0.38) | TSHRMAPK1KDM4EL3MBTL1MEN1 | |
| SCHEMBL6859354 | 0.81 | HSD17B10 (0.36) | TSHRMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL6858363 | 0.80 | PDE5A (0.41) | — | |
| SCHEMBL6657678 | 0.80 | EGLN1 (0.39) | TSHRMAPK1KDM4EL3MBTL1MEN1 | |
| SCHEMBL7674654 | 0.77 | PTPN12 (0.47) | TSHRMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL7656292 | 0.77 | NPC1 (0.53) | TSHRMAPK1KDM4EL3MBTL1MEN1 | |
| SCHEMBL6691209 | 0.76 | KDM4E (0.33) | TSHRMAPK1KDM4EL3MBTL1MEN1 | |
| SCHEMBL6901515 | 0.76 | TMIGD3 (0.45) | TSHRMAPK1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL6763425 | 0.75 | EGLN1 (0.42) | TSHRMAPK1KDM4EL3MBTL1MEN1 | |
| SCHEMBL6219167 | 0.73 | EGLN1 (0.41) | MAPK1KDM4EMEN1KMT2AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787548-B1 | CARDIOVASCULAR INSUFFICIENCY AND ERECTILE DYSFUNCTION; 3-(4-(3-CHLORO-4-HYDROXYBENZYLAMINO) BENZO(4,5)THIENO(2,3-D)PYRIMIDIN-2-YL)PROPIONIC ACID | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2004-09-07 | — | — | US | disclosed |
| US-6756375-B2 | ESTROGEN RECEPTOR MODULATION; HORMONE REPLACEMENT THERAPY | AKZO NOBEL N.V. (NL) | 2004-06-29 | — | — | US | disclosed |
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | MERCK PATENT GMBH (DE) | 2004-03-25 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030022906-A1 | Use of pde v inhibitors | MERCK PATENT GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| US-6495557-B1 | SUCH AS 3-(4-(3-CHLORO-4-METHOXYBENZYLAMINO)BENZO-(4,5)-THIENO (2,3-D)PYRIMIDIN-2-YL)PROPIONIC ACID; CARDIOVASCULAR DISORDERS AND/OR IMPAIRED POTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-12-17 | — | — | US | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | TSHR 1997/4885MAPK1 2856/4885KDM4E 3713/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | TSHR 530/4885MAPK1 3334/4885KDM4E 2219/4885 |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | PTGER1, PTGIS, PTGIR | TSHR 1110/4885MAPK1 2640/4885KDM4E 4841/4885 |
| US-20030022906-A1 | Use of pde v inhibitors | PDE3A, PDE5A, PDE2A | TSHR 4646/4885MAPK1 1218/4885KDM4E 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.